MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, today announces the completion of its latest funding round.
New funds to fight C. difficile
MGB Biopharma’s anti-bacterial agent for treatment of C. difficile infections, helped by Archangels funding round, to enter Phase II clinical trials